- Home
- CCEL vs LEXX Comparison
CCEL vs LEXX Comparison
Compare CCEL & LEXX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CCEL
- LEXX
- Stock Information
- Founded
- CCEL 1989
- LEXX 2004
- Country
- CCEL United States
- LEXX Canada
- Employees
- CCEL N/A
- LEXX N/A
- Industry
- CCEL Managed Health Care
- LEXX Biotechnology: Pharmaceutical Preparations
- Sector
- CCEL Health Care
- LEXX Health Care
- Exchange
- CCEL Nasdaq
- LEXX Nasdaq
- Market Cap
- CCEL 53.9M
- LEXX 49.3M
- IPO Year
- CCEL 1997
- LEXX N/A
- Fundamental
- Price
- CCEL $6.26
- LEXX $3.10
- Analyst Decision
- CCEL
- LEXX Strong Buy
- Analyst Count
- CCEL 0
- LEXX 2
- Target Price
- CCEL N/A
- LEXX $11.00
- AVG Volume (30 Days)
- CCEL 3.5K
- LEXX 93.9K
- Earning Date
- CCEL 10-22-2024
- LEXX 11-18-2024
- Dividend Yield
- CCEL N/A
- LEXX N/A
- EPS Growth
- CCEL N/A
- LEXX N/A
- EPS
- CCEL N/A
- LEXX N/A
- Revenue
- CCEL $31,641,636.00
- LEXX $411,019.00
- Revenue This Year
- CCEL $3.70
- LEXX $82.02
- Revenue Next Year
- CCEL $10.57
- LEXX $95.09
- P/E Ratio
- CCEL N/A
- LEXX N/A
- Revenue Growth
- CCEL 1.93
- LEXX 34.05
- 52 Week Low
- CCEL $3.67
- LEXX $0.90
- 52 Week High
- CCEL $9.50
- LEXX $6.85
- Technical
- Relative Strength Index (RSI)
- CCEL 45.11
- LEXX 46.94
- Support Level
- CCEL $6.29
- LEXX $2.92
- Resistance Level
- CCEL $6.80
- LEXX $3.39
- Average True Range (ATR)
- CCEL 0.28
- LEXX 0.19
- MACD
- CCEL 0.02
- LEXX -0.01
- Stochastic Oscillator
- CCEL 9.71
- LEXX 39.42
About CCEL Cryo-Cell International Inc.
Cryo-Cell International Inc is engaged in cellular processing and cryogenic storage. The company is organized into three reportable segments namely cellular processing and cryogenic storage, with a focus on the collection and preservation of umbilical cord blood and tissue stem cells for family use and the manufacturing of PrepaCyte CB units segment, which is a processing technology used to process umbilical cord blood stem cells. The Public cord blood banking segment consists of cellular processing and cryogenic storage of umbilical cord blood stem cells for public use. The company generates maximum revenue from cellular processing and cryogenic storage and it derives revenue from processing and testing fees and storage segment.
About LEXX Lexaria Bioscience Corp.
Lexaria Bioscience Corp's patented drug delivery technology, DehydraTECH improves the way active pharmaceutical ingredients enter the bloodstream by promoting more effective oral delivery. DehydraTECH has the ability to increase bio-absorption with cannabinoids and nicotine by 5-10x and, in some instances with cannabinoids by as much as 27x compared to standard industry formulations, reduce the time of onset from 1-2 hours to minutes, and mask unwanted tastes. DehydraTECH has also evidenced an ability to deliver some drugs more effectively across the blood brain barrier. The Company has four reportable segments: Intellectual Property Licensing, B2B Production, Research and Development and Corporate. It earns maximum revenue from Intellectual Property Licensing.